Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.

Brain tumor pathology - 1 Jan 2015

Kato Yukinari

Abstract excerpt

Mutations of isocitrate dehydrogenase 1/2 (IDH1/2) have been reported in gliomas and other types of tumors, such as acute myeloid leukemias, cartilaginous tumors, intrahepatic cholangiocarcinomas, osteosarcomas, and giant cell tumors of bone. In gliomas, IDH mutations uniformly occur in the functionally critical arginine 132 residue (R132) of IDH1 and arginine 172 residue (R172) of IDH2. IDH1 and IDH2 catalyze...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arginine
Share to Catalysis
Share to Cytosol

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Glutarates

Share to Isocitrate Dehydrogenase

Share to Ketoglutaric Acids

Share to Oxidation-Reduction

Source

Identifiers

PMID: 25324168
DOI: 10.1007/s10014-014-0202-4

Genes

IDH1
IDH2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.PMID 25324168Read ↗

A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation.Semantic proximity Read ↗

Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.Semantic proximity Read ↗

Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations.Semantic proximity Read ↗

Novel monoclonal antibodies GMab-r1 and LMab-1 specifically recognize IDH1-R132G and IDH1-R132L mutations.Semantic proximity Read ↗

Determining IDH-Mutational Status in Gliomas Using IDH1-R132H Antibody and Polymerase Chain ReactionSemantic proximity Read ↗

Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.Semantic proximity Read ↗

Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors.Semantic proximity Read ↗

Isocitrate dehydrogenase mutations in gliomas.Semantic proximity Read ↗

Diagnostic advantage of double immunohistochemistry using two mutation-specific anti-IDH antibodies (HMab-1 and MsMab-1) in gliomas.Semantic proximity Read ↗

Monoclonal antibody specific for IDH1 R132H mutation.Semantic proximity Read ↗

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.Semantic proximity Read ↗

Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.